Increased Release of Cytokines from Human Peripheral Blood Mononuclear Cells by the β-Galactoside-Specific Lectin from Clinically Applied Mistletoe Extract
Therapeutic modulation of immune functions offers an attractive concept in tumor therapy. The principal obstacle to the formulation of a rational approach to immunomodulation therapy is the only partially unravelled complexity of the relations between effector cell and a network of cytokines. Any contribution to the basic understanding of this aspect can be favorably translated into clinical benefit in hospital practice. Here we test the assumption that lectins have immunomodulatory potency by augmenting cytokine secretion, using the concept of the supposed physiological relevance of protein-carbohydrate interactions [1, 2]. The selection of the lectin was empirically based on the knowledge that a proprietary extract from mistletoe (Iscador), containing a ß-galactoside-specific lectin-I (ML-I), exhibits immunomodulatory potency [3, 4].
KeywordsCytolytic Activity Human Peripheral Blood Mononuclear Cell Viscum Album Peripheral Blood Mononuclear Cell Culture Specific Polyclonal Antibody
Unable to display preview. Download preview PDF.
- 2.Gabius HJ (1988) Mammalian lectin:their structure and their glycobiological and glycoclinical roles. ISI Atlas Sci Biochem 1:210–214Google Scholar
- 9.Ditter B, Becker KB, Urbaschek R, Urbaschek B (1983) Quantitativer Endotoxin-Nachweis. Automatisierter, kinetischer Limulus-Amöbozyten-Lysat-Mikrotiter-Test mit Messung probenabhängiger Interferenzen. Arzneimittelforschung 5:681–687Google Scholar